Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for BioInvent International AB's EV-to-OCF or its related term are showing as below:
BOVNF'
s EV-to-OCF Range Over the Past 10 Years
Min: -41.57 Med: -5.5 Max: 0.82
Current: -4.56
During the past 13 years, the highest EV-to-OCF of BioInvent International AB was 0.82. The lowest was -41.57. And the median was -5.50.
BOVNF's EV-to-OCF is ranked better than 52.98% of 1410
companies
in the Biotechnology industry
Industry Median: -3.52
vs BOVNF: -4.56
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BioInvent International AB (OTCPK:BOVNF) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BioInvent International AB's PE Ratio (TTM) for today is calculated as:
BioInvent International AB's share price for today is $3.2886.
BioInvent International AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.547.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
BioInvent International AB EV-to-OCF Related Terms
BioInvent International AB EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BioInvent International AB's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioInvent International AB EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioInvent International AB's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where BioInvent International AB's EV-to-OCF falls into.
BioInvent International AB's current Enterprise Value is $124.27 Mil.
BioInvent International AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-28.10 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioInvent International AB (BOVNF) has a EV-to-OCF of -4.42 as of Aug. 15, 2026. According to the industry distribution chart, BioInvent International AB ranks #663 out of 1410 companies in the Biotechnology industry, placing it in the top 47%.
Is BioInvent International AB's EV-to-OCF too high?
BioInvent International AB's current EV-to-OCF is -4.42. Based on the distribution chart, BioInvent International AB ranks #663 out of 1410 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BioInvent International AB has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does BioInvent International AB's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioInvent International AB ranks #663 out of 1410 companies for EV-to-OCF. This puts BioInvent International AB in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. BioInvent International AB's current EV-to-OCF is -4.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioInvent International AB stock overvalued right now?
BioInvent International AB (BOVNF) has a current EV-to-OCF of -4.42. The stock's GF Value™ is $6.44, compared to a current price of $3.29 — trading 48.9% below its estimated fair value. The current EV-to-OCF is -4.42. BioInvent International AB's overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For BioInvent International AB (BOVNF), the current EV-to-OCF is -4.42 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioInvent International AB (BOVNF) Overvalued in 2026?
Based on GuruFocus' analysis, BioInvent International AB stock appears to be undervalued.
The current stock price of $3.29 is trading 48.9% below its estimated GF Value™ of $6.44.
Key valuation signals for BOVNF:
EV-to-OCF: -4.42
GF Value™: $6.44 vs. price of $3.29 (48.9% below fair value)
No single metric tells the full story. See the BOVNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
44GF Score
Get the complete analysis for BOVNF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOVNF has been successfully added to your 
